NuScale CFO sells 20,000 shares as SMR drops 15.7%

AI power demand is still the trade, but execution is the bill

The nuclear trade has not gone away. It has simply become more selective. Hyperscalers still want reliable baseload power for AI data centers, and the market still likes the idea that nuclear can deliver what intermittent renewables cannot. That is why the names tied to the theme keep moving when the tape turns toward energy and infrastructure, and why the same handful of stocks keep getting re-rated on every new headline.

Cameco and BWX Technologies have been the cleaner expressions of that demand in a lot of screens because they sit closer to fuel, components, and the supply chain that can actually earn money before the first new reactor is humming. NuScale Power sits further out on the curve. It has the only U.S. Nuclear Regulatory Commission-approved SMR design, which is a real asset, but the market is no longer paying up just for regulatory novelty. It wants construction, contracts, and a path that does not keep slipping right.

That is the backdrop for NuScale Power Corp. The stock closed at $8.61 on September 11 after UBS cut it to Sell from Neutral and set a $6 target, citing execution risk. The shares fell 15.67% on heavy volume. You do not need much more than that to understand the mood around the name. The market is still willing to listen to the nuclear story. It is less willing to finance the timetable.

Why the market is still paying attention to SMR names

The macro force here is simple enough. AI data centers need power, and they need it on a scale that makes the old conversation about rooftop solar and battery smoothing look quaint. That has pulled nuclear back into the center of the energy debate, and it has given SMR developers a second life in public markets. The problem is that public markets are not buying the concept in the abstract anymore. They are buying the path to first deployment, and they are punishing anything that looks like a long slide from design approval to revenue.

NuScale’s second-quarter 2026 numbers did not help. Revenue came in at $0.1 million, down sharply year over year, while the company still reported roughly $1.9 billion in cash and investments. That combination matters because it tells you the company has time, but not necessarily momentum. Cash buys optionality. It does not buy a plant, a customer commitment, or a shorter regulatory path.

The peer set makes the contrast sharper. Cameco and BWX Technologies are often treated as better near-term ways to express the same nuclear renaissance because they are closer to the parts of the chain that can convert demand into cash flow sooner. Other advanced reactor developers, including names tied to hyperscaler partnerships such as Kairos Power and X-energy, are being framed by UBS as moving toward construction faster than NuScale. That is the market’s real filter right now. Not whether nuclear is back. Whether this specific company can turn a policy and AI theme into a build schedule.

August insider sales and the amended Form 4

The filing that matters here is the amended Form 4 reported on September 11, 2026. Chief Financial Officer Robert Ramsey Hamady exercised options for 20,000 shares at $3.20 each and sold the same 20,000 shares at $9.49 each on August 17, 2026. The gross value was about EUR 163,854 after euro-normalisation, and the sale was made under a Rule 10b5-1 plan adopted on March 31, 2026. That is the mechanical part. The market part is that this was not a one-off.

Hamady’s trade sits inside a cluster of insider sales in August 2026 that also included COO Carl M. Fisher and director Shinji Fujino. Our dossier shows 12 recent declarations and three distinct insiders in the cluster, with Hamady appearing more than once in the recent record. Earlier dispositions by executives and large shareholder Fluor Corp add to the same pattern in the months before. One filing does not make a thesis. A cluster does make you look twice, especially when it comes from a company whose equity story is still leaning on future milestones rather than current operating scale.

Insiders Trades data gives the filing some context, but not a verdict. The score rationale here is straightforward enough: the chief financial officer is a high-weight role in our scoring, the trade is part of an insider cluster, and the filing value is tiny relative to market value, under 0.01% of the company’s market cap. That last point matters. EUR 163,854 is real money for a person. It is not a balance-sheet event for a company with a market cap of about EUR 3.28 billion. You should read the trade as information about behavior, not as a capital allocation decision for the business.

Why the CFO sale matters in context

A CFO sale under a 10b5-1 plan is not the same thing as a panic exit. The plan was adopted months earlier, and the exercise-sale pair is a common way to monetize vested options. That is why the filing cannot be read as a clean negative on its own. But the market rarely looks at these things in isolation, and neither should you. When the CFO is selling into a period already marked by other insider dispositions, the trade lands differently than a lone, routine exercise in a quiet name.

The timing also matters. The sale came before the September 11 downgrade and the 15.67% drop, but after a stretch in which the stock had already been forced to defend the gap between the nuclear theme and the company’s own execution timeline. UBS said competitors are moving toward construction while NuScale’s estimated five-plus year build timeline and lack of firm customer commitments present meaningful challenges. The firm modeled only one project beginning construction in 2028 and cumulative cash burn of $700 million from 2026 to 2028. That is the kind of note that changes how a market reads insider activity. A sale that might have looked routine in a momentum phase starts to look more like a management team taking some chips off the table while the street focuses on the hard part.

The stock’s own fundamentals do not offer much of a cushion. Insiders Trades data rates the company at 22 on its fundamental score, with a quality score of 29 and a value score of 15. Those are not disaster numbers, but they are not the sort of readings that make a long-dated execution story easy to own through a downgrade. The company still has the only approved U.S. SMR design. It still sits in a sector with real policy and AI demand support. It still has cash. It also still has to prove that the market can move from enthusiasm to construction without losing patience.

NuScale’s advantage is real, but the market wants proof

NuScale’s strongest argument is still the same one it has had for a while. It owns the only U.S. NRC-approved SMR design. In a sector where regulatory friction can kill years of work, that matters. It gives the company a credibility edge that many rivals do not have. It also gives the stock a way to stay in the conversation when the nuclear theme catches a bid on AI power demand or domestic energy policy.

But the market is not paying for design approval alone anymore. It wants to know who is actually going to build, when, and with what customer commitment. That is where NuScale keeps running into trouble. UBS’s note was blunt about the gap between the company’s timeline and the pace of competitors. The estimated five-plus year build timeline is a long time in a market that has already moved from story stock enthusiasm to a more selective phase. If you are trying to own the name, you are effectively underwriting patience.

The company’s liquidity position helps, but only up to a point. Roughly $1.9 billion in cash and investments gives NuScale room to keep working. It does not remove the need for a commercial catalyst. That is why the stock can still trade like a theme name one week and a financing-duration debate the next. The market is not confused. It is just alternating between two very different ways of valuing the same company.

The insider cluster is the sharper tell than the single sale

The single sale is easy to overread. The cluster is harder to ignore. Our data shows three insiders in the recent pattern, 12 recent declarations, and sales from the CFO, the COO, and a director. That is the part that deserves attention, because it tells you the activity is not just one executive cleaning up a vesting schedule. It is a broader pattern of monetization around the same name.

Still, you should keep the scale in view. The filing value is tiny relative to market cap. The company is not being drained by insider selling. What the cluster does is change the tone. It says that multiple insiders have chosen to reduce exposure while the stock is still being priced on a future build story. That is a different read from a boardroom full of buyers leaning into a dislocated share price. It does not tell you the business is broken. It does tell you that management and directors are not using their own stock as a loud public vote of confidence right now.

The historical cohort data is useful here because it keeps the discussion grounded. For CFO buys at large-cap names, Insiders Trades data shows a 59.6% win rate over 90 days and an average 90-day return of 4.23%, with a 365-day average return of 81.53%. That is a real historical pattern, but it is not a forecast for this trade, and it is not even the same direction. This filing is a sale, not a buy. So the cohort read is background, not a crutch. It tells you how we have seen similar role-and-size buckets behave over time. It does not rescue a weak setup or condemn a strong one.

What to watch before the next filing lands

The next catalyst is not another insider form. It is whether NuScale can produce evidence that narrows the gap between the nuclear narrative and actual deployment. Watch for customer commitments, construction milestones, and any update that changes the market’s view of the five-plus year build timeline. If the company keeps talking about the same long runway while peers keep moving toward construction, the stock will remain vulnerable to every downgrade and every insider sale that lands on the tape.

You should also watch how the market treats the broader nuclear basket. If Cameco, BWX Technologies, and the more advanced reactor names keep attracting capital while NuScale lags, that will tell you the market is not abandoning nuclear. It is sorting winners by proximity to revenue. That is a useful distinction. It means the theme can stay hot while this stock stays under pressure.

For now, the filing adds to a pattern rather than creating one. A CFO sold 20,000 shares at $9.49 after exercising at $3.20. The sale sat inside a three-insider cluster. UBS cut the stock to Sell and pointed to execution risk. The company still has the only approved U.S. SMR design, but the market is asking for more than that, and it is asking now.

Filing trail and sector backdrop

The filing trail is straightforward. The amended Form 4 was reported on September 11, 2026, and the stock reaction and downgrade were covered the same day. The sector backdrop comes from reporting on AI data center power demand and the renewed nuclear trade, while the company’s second-quarter revenue and liquidity figures came from earnings coverage.

The point is not that one source settles the case. It is that the same story keeps showing up from different angles. The nuclear theme is real. The execution gap is real. The insider cluster sits between those two facts and makes the stock a little less easy to own on faith.

This is not investment advice.

Dig deeper: Hamady Robert Ramsey's filing track record.

This is not investment advice.